Mental and Substance Use Disorders Prevalence Study (MDPS), United States, 2020-2022

The Mental and Substance Use Disorders Prevalence Study (MDPS) is a pilot program designed to estimate the prevalence of specific mental and substance use disorders among U.S. adults 18-65 years of age. The MDPS is also designed to estimate the percentage of individuals with these specific mental and substance use disorders who receive treatment. The study is funded by SAMHSA.
To estimate the prevalence of specific mental and substance use disorders, the MDPS design addresses two gaps in prior general population survey efforts: (1) the
exclusion of institutionalized populations at high risk for disorders, and (2)
the reliance on nonclinical or screening scales to estimate mental and
substance use disorders. The specific disorders of interest measured in the MDPS
are past 12-month and lifetime schizophrenia spectrum disorders (defined as
including schizophrenia, schizoaffective disorder, or schizophreniform), past
12-month bipolar I disorder, major depressive disorder (MDD), generalized
anxiety disorder (GAD), posttraumatic stress disorder (PTSD), obsessive-compulsive
disorder, anorexia nervosa, and past 12-month alcohol, opioid, cannabis,
stimulant, and sedative/hypnotic/anxiolytic use disorders. The MDPS sample
included individuals residing in the residential household population and in three
non-household populations: state/federal prisons, state psychiatric hospitals, and
homeless shelters. The MDPS also utilizes the Structured Clinical Interview for
DSM-5 (SCID-5; First et al., 2015), delivered by trained mental health
clinicians, which is the gold standard for mental and substance use disorder
diagnostic assessment. The MDPS was a cooperative agreement between RTI
International and Substance Abuse and Mental Health Services Administration (SAMHSA).